No Products in the Cart
The U.S. Food and Drug Administration (FDA) recognized cannabidiol as a medicine for the first time on June 25, 2018 for the treatment of two severe pediatric epileptic disorders, Lennox-Gastaut syndrome and Dravet syndrome.
The healing potentials of CBD can be seen concretely through patients being treated with the almost pure CBD formulation, Epidiolex. The agency stated that Epidiolex is an effective and safe product for patients 1 years old and older. Epidiolex can also serve patients suffering from seizures due to tuberous sclerosis complex. This drug contains plant-derived purified CBD and is only available by a prescription from a licensed medical professional.
The Drug Enforcement Administration (DEA) took off Epidiolex from the Schedule l Drug List, a category deemed for drugs that have no medical use and a high potential for abuse, and placed it on the least harmful drug list, Schedule V. The DEA then removed it completely from the federal government’s list of controlled substances because of its medicinal value. This was a historic decision since all cannabis-derived products have never been classified as anything other than a Schedule l Drug.